| goremedical.com | gore.com | all products | careers | ||
| Subscribe | Contact Us | ||
![]() |
||
|
NEWS
CASE STUDY
ENDO UPDATE
PRODUCT UPDATES
|
REIMBURSEMENT CORNER
CLINICAL STUDIES
EVENTS
CLINICAL LITERATURE
|
||||
| Printable PDF Version | Download Adobe Reader | |||||
| BACK to TOP | |||
The Evolution of Design |
|||
| W. L. Gore & Associates (Gore) has made a number of modifications to the GORE VIABAHN® Endoprosthesis, demonstrating the company's commitment to continuously providing its customers with innovative solutions. Recently Gore received approval from the US Food and Drug Administration (FDA) to market the most up-to-date design of the GORE VIABAHN® Endoprosthesis for device diameters 9 - 13 mm. The large diameter product now enables streamlined deployment on the same 0.035" guidewire and TIP to HUB direction as the 5 - 8 mm sizes. Additional modifications to the large diameter GORE VIABAHN® Endoprosthesis include heparin bioactive surface, radial device expansion and a lower profile that is now available for some configurations. More | |||
| BACK to TOP | |||
Revascularization of the Iliac Artery with the GORE VIABAHN® Endoprothesis with Heparin Bioactive Surface*Jeffrey D. Trachtenberg, MD, St. Mary's Hospital, Decatur, Illinois CLINICAL CHALLENGESThe patient is a 62-year-old man with known peripheral arterial disease who is status post-stenting of the left common iliac and superficial femoral arteries in 1998. The patient presented with worsening short distance claudication of the right lower leg. His past medical history includes coronary artery disease, hypertension and hypercholesterolemia. He is a former smoker, having quit in 2005. His current medications include atorvastatin, diltiazem and aspirin. His ankle brachial index on the right was 0.52 and on the left was 0.84. Arterial duplex suggested a right iliac occlusion and this was confirmed by CT angiogram (Figure 1). More |
|||
| BACK to TOP | |||
Investigation of the Hemodynamic Effect of StentWires on Renal
|
|||
| BACK to TOP | ||||||||||||||||||||||||||||||||||||||
New GORE PROPATEN® Vascular Graft Line Extensions ReleasedTo continue to meet your needs, we have released additional catalogue numbers to the family of GORE PROPATEN® Vascular Grafts.
|
||||||||||||||||||||||||||||||||||||||
| BACK to TOP | |||
Highlights of the Medicare Final FFY2010 and Proposed CY2010 RulesMedicare CY2010 Proposed Rule for the Physicians Fee Schedule Payment PoliciesThe Medicare CY 2010 Proposed Rule for Payment Policies paid under the Physicians Fee Schedule was put on public display on July 1, 2009. This proposed rule contains two provisions that have potential significant impact to physician payments. The first is new survey data that CMS has incorporated into the PE (practice expense) component of the RVU (relative value unit) calculation for CY2010. This results in significant RVU shifts between certain CPT® Codes. The AMA administered a new survey in CY2007 and CY2008, the PPIS (Physician Practice Information Survey) with 51 medical specialty and health care professional groups. CMS believes it to be the most comprehensive PE source of data to date. The second significant provision is the conversion factor amount which is used to convert the RVUs to the Physicians Fee Schedule Payments. The methodology is mandated by Congress and termed the SGR (sustainable growth rate). The proposed CY2010 SGR amount is a decrease of 21.5% from the CY2009 SGR amount. In past years, a similar significant decrease was proposed and it was moderated by Congress. There are provisions in the current proposed Congressional Health Care Reform bills to revise the SGR calculation. The AMA and specialty medical societies may have more information regarding this issue. The Medicare Final CY 2010 rule will be posted no later than October 31, 2009 and will be effective January 1, 2010. Medicare FFY2010 Final Rule for the Hospital Inpatient Prospective Payment System (IPPS)The Medicare FFY 2010 Final Rule for the Hospital Inpatient Prospective Payment System (IPPS) was posted on August 1, 2009. Hospital inpatients are paid on a per admission basis under the MS-DRG methodology. The FFY2010 relative weight calculations were based on the final transition year of a cost-based method from a charge-based method. The payment rates as published in the FFY 2010 Final Rule were slightly increased over the FFY 2010 Proposed Rule. This increase was in part due to no payment reduction for the documentation and coding adjustment. This FFY2010 Final Rule provisions will be effective October 1, 2009. Medicare CY2010 Proposed Rule for the Hospital Outpatient Prospective Payment System (OPPS) and the Ambulatory Surgery Center (ASC)The Medicare CY2010 Proposed Rule for the OPPS resulted in slight increases in most payments and no other significant changes. The Medicare CY2010 Proposed Rule for the ASC continues the payment methodology transition to a percentage of the OPPS payment amounts. The Final CY2010 Final OPPS and ASC rules will be posted no later than October 31, 2009 and effective January 1, 2010. Gore is available to answer your reimbursement questions. For more information, contact Antoinette Sheen, Coverage, Coding & Reimbursement Specialist. Email: asheen@wlgore.com 928.864.2420 toll free 800.528.1866 ext. 42420 |
|||
| BACK to TOP | |||||||||||||||||||||||
|
|||||||||||||||||||||||
| BACK to TOP | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| BACK to TOP | |||
Dialysis AccessDavidson I, Hackerman C, Kapadia A, Minhajuddib A. Heparin bonded hemodialysis e-PTFE grafts result in 20% clot free survival benefit.Journal of Vascular Access 2009;10(3):153-156. Peripheral Vascular TreatmentLösel-Sadée H, Alefelder C. Heparin-bonded expanded polytetrafluoroethylene graft for infragenicular bypass: 5-year results.Journal of Cardiovascular Surgery 2009;50(3):339-343. Malignant Jaundice TreatmentKrokidis M, Fanelli F, Orgera G, Bezzi M, Passariello R, Hatzidakis A. Percutaneous treatment of malignant jaundice due to extrahepatic cholangiocarcinoma: covered Viabil stent versus uncovered Wallstents. Cardiovascular & Interventional Radiology. In press.AAASociety for Vascular Nursing (SVN) Task Force for Clinical Practice Guideline. 2009 clinical practice guideline for patients undergoing endovascular repair of abdominal aortic aneurysms (AAA). Journal of Vascular Nursing 2009;27(2):48-63.Thompson J, Bertling G. Endovascular leaks: perioperative nursing implications. AORN Journal 2009;89(5):839-850. Sun Z, Chaichana T. Investigation of the hemodynamic effect of stent wires on renal arteries in patients with abdominal aortic aneurysms treated with suprarenal stent-grafts. Cardiovascular & Interventional Radiology 2009;32(4):647-657. Schwarze ML, Shen Y, Hemmerich J, et al. Age-related trends in utilization and outcome of open and endovascular repair for abdominal aortic aneurysm in the United States, 2001-2006. Journal of Vascular Surgery. In press. Waasdorp EJ, de Vries JPPM, Sterkenburg A, et al. The Association between Iliac fixation and proximal stent-graft migration during EVAR follow-up: mid-term results of 154 Talent devices. European Journal of Vascular & Endovascular Surgery 2009;37(6):681-687. |
|||
| © 2009 W. L. Gore & Associates, Inc. | Legal Information | Privacy Policy | Regulatory Information | Trademarks |